yourstate.us
42 CFR 24.4

§ 24.4 Eligibility.

United States · 42 CFR — Public Health · Status: effective

Get this as JSONEmbed this
Cite this
Citation
42 CFR 24.4, § 24.4 Eligibility, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/200625
Permanent ID
ys:prov:200625@1
SHA-256
616bbc9e2d5754d54863e8f869ff5b9c2fd7f81cb0ae00f71c96e8f22010a2e2

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) No individual may be appointed to the SBRBPAS unless such individual: (1) Has earned a doctoral level degree in biomedicine or a related field, or a doctoral or master's level degree in engineering, bioinformatics, or a related or emerging field; and (2) Meets the qualification standards prescribed by the Office of Personnel Management for appointment to a position at GS-15 of the General Schedule. (b) Individuals eligible under paragraph (a) of this section shall be experts outstanding in the field of biomedical research, clinical research evaluation, or biomedical product assessment. The criteria in paragraphs (c) through (e) of this section are indicators that the individual is considered an expert outstanding in their respective field. (c) An individual will be considered an expert outstanding in biomedical research when the individual is actively engaged in original biomedical research, including behavioral research, and whose work in this area is considered by recognized experts or peers to be outstanding. One or more of the following achievements will indicate the individual has been recognized by experts or peers as outstanding: (1) Conducted original research that has been published in peer-reviewed journals of high stature; (2) Received major prizes and awards (such as visiting professorships and named lectureships) in recognition of original contributions to research; (3) Received invitations to speak at or to chair major national or international meetings or symposia; (4) Been elected to membership in professional societies of high stature; or (5) Meet other criteria demonstrating sufficient rigor or accomplishment in a field that is relevant and necessary to the accomplishment of the agency's mission. (d) An individual will be considered an expert outstanding in Clinical Research Evaluation when the individual is actively engaged in clinical research evaluation and is considered by recognized experts or peers to be outstanding. One or more of the following achievements will indicate the individual has been recognized by experts or peers as outstanding: (1) Significant experience dealing with complex, precedent-setting evaluation issues, including those arising during product development, that involved significant scientific controversy, had far reaching implications for clinical research or resulted in a widespread economic effect in the health-care delivery system; (2) Taken an active role in the development of significant scientific or regulatory guidelines for clinical research evaluation; (3) Been the recipient of invitations to speak at or to chair major national or international meetings and symposia; or (4) Meet other criteria demonstrating sufficient rigor or accomplishment in a field that is relevant and necessary to the accomplishment of the agency's mission. (e) An individual will be considered an expert outstanding in biomedical product assessment when an individual is actively engaged in the development or assessment of biomedical products and whose work in this area is considered by recognized experts or peers to be outstanding. One or more of the following achievements will indicate the individual has been recognized by experts or peers as outstanding. (1) Significant experience dealing with complex, precedent-setting evaluation, scientific policies or development issues (e.g., those associated with novel biomedical products, novel approaches to biomedical product-manufacturing, or use of novel evaluation methods); (2) Demonstrated cutting-edge expertise in a scientific or technical discipline critical to design, development, manufacturing, clinical performance assessment, or other technical aspects of effective oversight of biomedical products; (3) Played a leadership role in planning and conducting public meetings to seek public input and communicate regulatory scientific policies; (4) Been the recipient of invitations to speak at or to chair major national or international meetings and symposia; or (5) Meet other criteria demonstrating sufficient rigor or accomplishment in an activity or field that is relevant and necessary to the accomplishment of the agency's mission.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.